This section of the Knowledge Centre provides information on the various options available for oral anticoagulation. With oral vitamin K antagonists (VKAs) and non-vitamin K oral anticoagulants (NOACs) being covered, you'll be able to understand the merits and drawbacks of individual treatments, such as warfarin, rivaroxaban and edoxaban, in detail.
Details of the effects that VKAs can have on patients with atrial fibrillation, heart failure, valvular heart disease, venous thromboembolism and transient ischaemic attacks; the use of paracetamol and an adjuvant therapy; how the CYP2C9 and VKORC1 genes affect blood coagulation; and details of non-vitamin K oral anticoagulants, such as factor Xa inhibitors, rivaroxaban, apixaban, edoxaban, and the factor IIa inhibitor dabigatran are all included in this section.
Learn about the various oral vitamin K antagonists such as warfarin, rivaroxaban, apixaban and acenocoumarol, and what conditions they can be used to treat, like heart failure and valvular heart disease.
Explore non-vitamin K oral anticoagulants approved for the prevention of stroke in patients with non-valvular atrial fibrillation.
Alternatively login via
Back to epgonline.org